Ajanta Pharma has entered into an in-licensing agreement with Biocon for Semaglutide, a GLP-1 receptor agonist. Under the agreement, Biocon will supply Semaglutide to Ajanta for exclusive marketing in 23 countries and semi-exclusive marketing in 3 countries across Africa, the Middle East and Central Asia.
Semaglutide, the GLP-1 receptor agonist, is to improve glycaemic control in adults. The product patent expires in most of these markets in March 2026. Ajanta plans to commercialize the products after receiving the regulatory approvals, which are expected in late 2026 or early 2027.
Ajanta has been one of the pioneers among Indian companies to build a strong branded generic business with own field force in over 30 countries across Africa, South-East Asia, Central Asia and the Middle East. In these markets, company has presence in a wide range of therapeutic segments like, Cardiology, Antidiabetic, Ophthalmology, Antibiotic, Antimalarial, Pain, Gynaecology, Paediatric and General Health products.
Ajanta Pharma is a specialty pharmaceutical formulation company having major focus on branded generic business across India, Asia & Africa.
